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operative blood losses continue to contribute to the mor-
bidity associated with cardiac surgery with CPB. The
bleeding complications are mainly due to problems relat-
ed to heparin, fibrinolysis, and loss of platelet numbers
and function.1 Platelet losses and dysfunction are primar-
ily due to hemodilution, adhesion to biomaterials,2
aggregation with other platelets and blood cells,3 release
of granule contents, and complete or partial destruction,
with the formation of platelet microparticles.4,5
Platelet anesthesia is a strategy to preserve platelet
numbers and function during cardiac surgery with CPB
by inhibiting platelets to prevent activation in both the
wound and the extracorporeal perfusion circuit.6 Ideally
the inhibitor must disappear or be completely reversed
at the time that protamine is given to restore clotting.
The goal of this strategy is a normal bleeding time, an
overall measure of platelet function, at the time that
protamine is given.
C ardiac operations require full anticoagulation duringcardiopulmonary bypass (CPB) and complete rever-
sal immediately afterward. Despite drawbacks, heparin
and its inhibitor protamine meet this requirement.
Nevertheless, bleeding complications and excessive post-
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PLATELET ANESTHESIA WITH NITRIC OXIDE WITH OR WITHOUT EPTIFIBATIDE DURING 
CARDIOPULMONARY BYPASS IN BABOONS
Nitric oxide (NO) is a reversible, potent platelet
inhibitor7 that can be given in the sweep gas of the oxy-
genator during CPB; however, because of an excep-
tionally short half-life in blood,8 the chemical is inac-
tive by the time that arterial blood reaches the patient.
Eptifibatide (Integrilin; COR Therapeutics Inc, South
San Francisco, Calif) is a short-acting, reversible
platelet glycoprotein (Gp) IIb/IIIa membrane receptor
inhibitor.9 Eptifibatide is a synthetic cyclic peptide that
contains a modified lysine–glycine–aspartic acid
sequence and is based on the structure of the disintegrin
barbourin.10 During CPB in baboons, eptifibatide pre-
vents platelet adhesion and aggregation and restores
bleeding times to the normal range within an hour after
protamine administration.11
NO and eptifibatide inhibit platelets by different
mechanisms and therefore are potentially synergistic
inhibitors. Synergistic inhibition offers the possibility
of more complete inhibition of platelet activation dur-
ing CPB and more rapid reversal at the end.12 This
study tested the hypothesis that the combination of NO
and eptifibatide provides complete platelet anesthesia
during CPB in baboons and restores bleeding time to
baseline values at the time that protamine is given, 15
minutes after CPB ends.
Methods
Juvenile baboons (Papio anubis) quarantined for at least 6
weeks and weighing 13 to 20 kg were used. For each study
the baboon was placed in a squeeze cage, the animal was
sedated intramuscularly with 10 mg/kg ketamine hydrochlo-
ride, and anesthesia was induced intravenously with 5 mg/kg
thiopental sodium. The animal was intubated and general
anesthesia was maintained with inhalational isoflurane. The
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Table I. Measured blood and plasma constituents
Group Base HEP START END PROT
Platelet count 1 100 101.8 ± 7.3 77.3 ± 7.2 61.1 ± 7.4* 55.5 ± 8.0*
(% of baseline) 2 100 93.9 ± 6.7 95.0 ± 7.9 96.7 ± 7.5† 74.7 ± 6.6
3 100 97.8 ± 2.8 78.4 ± 5.6 103.7 ± 3.3† 76.3 ± 2.3
Raw platelet count 1 100 100.4 ± 7.6 39.1 ± 3.9* 39.6 ± 5.0* 44.1 ± 6.3*
(% of baseline) 2 100 94.3 ± 6.7 47.3 ± 4.2* 55.5 ± 3.1*† 55.4 ± 4.4*
3 100 98.9 ± 2.3 42.1 ± 5.0* 68.0 ± 4.3*† 59.9 ± 3.0*
Platelet aggregation 1 100 97.7 ± 2.6 67.6 ± 2.1* 55.4 ± 7.5* 55.2 ± 6.2*
(% of baseline) 2 100 92.2 ± 8.7 77.3 ± 4.3* 83.4 ± 4.1 81.9 ± 3.7†
3 100 99.6 ± 4.9 0 ± 0*† 71.1 ± 4.5* 78.8 ± 4.5*†
b TG (ng/mL) 1 15.0 ± 2.8 20.0 ± 3.6 52.9 ± 15.5 120.1 ± 16.1* 60.9 ± 10.3
2 29.2 ± 8.5 22.7 ± 5.4 22.6 ± 6.3 56.9 ± 13.2† 35.6 ± 6.1
3 27.1 ± 7.9 32.1 ± 8.4 18.3 ± 6.8 49.7 ± 11.7† 29.2 ± 6.2
Bleeding time (min) 1 4.1 ± 0.4 15.8 ± 1.4*
2 3.8 ± 0.2 8.3 ± 1.4*†
3 3.8 ± 0.1 5.1 ± 1.2*†
Fragment 1.2 (nmol/L) 1 1.48 ± 0.28 1.74 ± 0.21 2.49 ± 0.87 3.89 ± 0.86 2.85 ± 0.34
2 1.57 ± 0.21 1.39 ± 0.15 1.45 ± 0.19 2.58 ± 0.62 2.45 ± 0.37
3 1.24 ± 0.09 1.25 ± 0.11 1.42 ± 0.12 2.59 ± 0.58 2.59 ± 0.51
Thrombin-antithrombin 1 21.6 ± 9.4 21.7 ± 5.0 19.5 ± 12.0 57.5 ± 14.7 41.9 ± 10.2
complex (m g/ mL) 2 19.8 ± 4.0 19.9 ± 3.7 8.9 ± 1.3 59.3 ± 12.5* 50.7 ± 7.6*
3 12.9 ± 3.0 14.9 ± 2.8 12.3 ± 4.2 65.5 ± 14.4* 51.4 ± 11.9
White blood cell count 1 100 114.2 ± 7.8 90.2 ± 18.8 243.4 ± 44.7* 175.4 ± 23.3
(% of baseline) 2 100 105.1 ± 3.0 76.5 ± 8.5 165.4 ± 23.1 151.6 ± 23.1
3 100 100.5 ± 1.8 70.3 ± 10.9 186.6 ± 35.5 131.2 ± 24.1
Hematocrit (%) 1 32.5 ± 0.5 32.0 ± 0.4 16.5 ± 0.9* 21.1 ± 0.7* 25.9 ± 0.6*
2 33.8 ± 0.8 34.0 ± 1.2 17.2 ± 1.4* 20.0 ± 1.7* 25.4 ± 1.5*
3 32.8 ± 0.6 33.3 ± 0.7 17.5 ± 1.3* 21.6 ± 1.3* 25.8 ± 1.3*
Data are mean ± SEM. P values are for group (drug) and time effects and group-time effects by 3-way ANOVA with the Bonferroni adjustment for repeated measures.
When the group effect is significant, results for 2-way ANOVA for each treatment group against the control group are also listed. Base, Baseline; HEP, after heparin
and drugs, before CPB; START, 5 minutes after starting CPB; END, 55 minutes after starting CPB; PROT, 10 minutes after protamine administration (25 minutes after
stopping CPB; 30, 30 minutes after time PROT; 60, 60 minutes after time PROT; 120, 120 minutes after time PROT.
*Significant differences (P < .05) between baseline and subsequent time points within groups. Raw indicates percentage change of actual platelet counts that are not
corrected for hemodilution. Mean (± SE) baseline platelet counts are 285,571 ± 31,762 cells/ m L for group 1 (control); 301,857 ± 42,585 cells/ m L for group 2 (NO
alone); and 295,571 ± 15,810 cells/ m L for group 3 (combination).
†Significant differences (P < .05) between specific treatment groups and control group at specific time points (unpaired t statistic).
right or left side of the neck and both groins were prepared
and draped appropriately for sterile cutdown and cannulation
of vessels. Hemodynamic monitoring was accomplished with
an arterial line with a 22-gauge catheter placed in the femoral
artery and a 5F Swan-Ganz catheter (Baxter Healthcare Corp,
Edwards Division, Santa Ana, Calif) placed in a femoral vein.
After anticoagulation with porcine sodium heparin (300
U/kg; Elkins-Sinn, Inc, Cherry Hills, NJ) a 10F to 14F Bio-
Medicus wire-wrapped, polyurethane catheter (Medtronic
Bio-Medicus, Inc, Eden Prairie, Minn) was introduced into
the jugular vein and advanced into the right atrium. A similar
but shorter 8F arterial catheter was inserted into the femoral
artery for reinfusion. All animals received humane care in
compliance with the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Laboratory
Animal Resources and published by National Institutes of
Health (NIH Publication No. 86-23, revised 1985). This
study was approved by the Institutional Animal Care and
Utilization Committee of the University of Pennsylvania.
The bypass circuit consisted of silicone elastomer tubing
(Dow Corning Inc, Midland, Mich); 2 polyurethane, wire-
wrapped cannulas (Medtronic Inc, Eden Prairie, Minn); a bub-
ble oxygenator (Bentley 5 Pediatric; Baxter Healthcare, Inc,
Irvine, Calif)13; an arterial line filter (Intersept Pediatric,
Medtronic Inc, Anaheim, Calif); and a roller pump (Sarns
model 13400; Sarns Inc, Ann Arbor, Mich). The oxygenator
was ventilated with 95% oxygen and 5% carbon dioxide at 3
L/min. Because the mechanism of platelet activation and
injury is similar with the 2 types of oxygenator,14 a bubble
oxygenator rather than a membrane oxygenator was used to
increase the robustness of the model.13 Baboon platelets are
less sensitive than human platelets to many platelet agonists.13
This perfusion system required only 500 mL Normosol
solution (Abbott Laboratories, North Chicago, Ill) for prim-
ing. Normothermic bypass was begun at 50 mL · kg–1 · min–1,
or approximately half the normal cardiac output. The heart
continued to eject and supply approximately half of the cir-
culation. Perfusion was maintained for 60 minutes, at which
time CPB was terminated.
Animals were divided into 3 groups. Group 1 (n = 7) was
the control group. In group 2 (n = 7) 800 ppm NO in nitrogen
(Puritan-Bennett, Carlsbad, Calif) was blended with nitrogen
(Bird air-oxygen blender; Bird Products Corp, Palm Springs,
Calif). Beginning 30 seconds before perfusion the blender
output was added to the oxygenator sweep gas to produce a
mixed concentration of 80 ppm NO and approximately 85%
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P values
30 60 120 Drug Time Drug-time One-way ANOVA
52.8 ± 6.9* 59.4 ± 7.4* 56.7 ± 8.4* .0001 .0001 .0001
82.1 ± 8.1† 82.0 ± 6.6† 80.9 ± 6.7 .008
80.9 ± 2.7† 90.3 ± 4.5† 94.0 ± 12.2† .004
41.6 ± 5.5* 47.8 ± 5.5* 44.6 ± 6.7* .014 .0001 .0001
63.1 ± 5.2*† 65.0 ± 5.0* 62.2 ± 4.3* .039
65.6 ± 3.7*† 75.2 ± 5.9*† 71.9 ± 3.8*† .005
53.2 ± 5.0* .0001 .0001 .0001
93.5 ± 1.7† .001
82.7 ± 4.4*† .325
27.3 ± 4.3 .07 .0001 .0001
27.4 ± 7.4 .063
22.1 ± 7.0 .034
14.8 ± 1.2* 14.4 ± 0.9* 14.3 ± 1.3* .0001 .0001 .0001
5.8 ± 0.4† 5.1 ± 0.4† 4.5 ± 0.3† .0001
4.9 ± 0.2† 4.5 ± 0.3† 4.2 ± 0.2† .0001
2.56 ± 0.26 .177 .0001 .787
2.24 ± 0.30 .153
1.82 ± 0.26 .082
28.7 ± 5.6 .991 .0001 .778
36.2 ± 5.4 .943
40.9 ± 10.8 .897
226.6 ± 24.3* 300.3 ± 23.6* 364.0 ± 36.4* .363 .0001 .919
208.4 ± 18.7* 276.5 ± 15.9* 315.5 ± 29.0* .209
211.1 ± 26.2 279.0 ± 25.9* 338.5 ± 35.7* .248
25.7 ± 0.8* 26.3 ± 0.9* 25.5 ± 0.6* .864 .0001 .797
26.5 ± 1.6* 27.1 ± 1.5* 26.5 ± 1.8* .667
26.7 ± 1.7 27.2 ± 1.3 26.4 ± 2.1 .625
concentration of oxygen. NO concentration was measured
with the NOxBOX II electrochemical analyzer (Bedfont
Scientific, Bedfont, United Kingdom). In group 3 (n = 7) NO
was given as in group 2 and a bolus injection of eptifibatide
(200 m g/kg) was administered before the start of CPB.
Eight blood samples (15-20 mL) were obtained at baseline
before administration of heparin and platelet inhibitors, 2
minutes after heparin and platelet inhibitor administration but
before CPB, 5 minutes after the start of CPB, 55 minutes after
the start of CPB, 10 minutes after administration of 3 mg/kg
protamine (25 minutes after the end of CPB), and 30, 60, and
120 minutes after the protamine sample was taken. Note that
protamine was given 15 minutes after CPB ended and that the
protamine sample was taken 10 minutes after that, or 25 min-
utes after CPB ended.
Blood samples were assayed for hematocrit, platelet count,
white blood cell count, platelet aggregation in response to
adenosine diphosphate (ADP), b -thromboglobulin (b TG)
release, prothrombin fragment 1.2, and thrombin-antithrom-
bin complex. Dilutions of formed blood elements and plasma
markers were corrected using hematocrit.
Heart rate was continuously monitored electrocardiograph-
ically. Systemic arterial, central venous, and pulmonary arte-
rial pressures were continuously monitored (Hewlett-Packard
78534C, Hewlett-Packard Company, Palo Alto, Calif).
Intermittent thermodilution cardiac outputs were measured
before and after CPB (Oximetrix 3 SO2/CO computer; Abbott
Laboratories, Abbott Park, Ill).
Measurements. Platelets were counted by phase
microscopy or by Coulter Counter (model STKR; Coulter
Corporation, Hialeah, Fla) in triplicate. For platelet studies
blood (8 mL) was anticoagulated with 1 mg D-phenylalanine-
proline-arginine-chloromethyl-ketone.15 Platelet-rich plasma
was obtained by centrifuging whole blood at 150g for 10 min-
utes. Platelet-poor plasma was prepared by centrifugation at
13,600g for 5 minutes. The platelet count of platelet-rich plas-
ma was adjusted to 150,000 cells/m L by dilution with platelet-
poor plasma for aggregation in response to ADP with a Payton
aggregometer (model 440; Chrono-Log, Inc, Havertown, Pa).
The concentration of ADP (5-50 m mol/L) required to produce
complete second-wave aggregation was measured; complete
second-wave aggregation was assumed when light transmis-
sion was 62.5% or greater within 5 minutes.16 The concentra-
tion of ADP required to obtain full aggregation of the baseline
sample was determined and the percentage aggregation was
normalized to 100%. In subsequent samples the percentage
aggregation observed at that ADP concentration was propor-
tionally normalized to the baseline value.
For plasma b TG analysis blood was withdrawn into cen-
trifugation tubes containing 10% (by volume) of 3.8% acid
citrate dextrose and alprostadil (prostaglandin E1) solution at
0°C. b TG was measured by radioimmunoassay.17
Template bleeding times were measured in duplicate on the
forearm with a blood pressure cuff inflated to 40 mm Hg at
baseline and at 4 time points after protamine administration.
The Simplate II (Organon Teknika Corporation, Durham,
NC) lancet was used to create reproducible skin incisions for
determinations of bleeding time.
Plasma levels of fragment 1.2 (Behring Diagnostics, Inc,
Westwood, Mass) and thrombin-antithrombin complex
(Behring Diagnostics) were measured by enzyme-linked
immunosorbent assay with commercial assay kits.
Statistical analysis. Data points represent the mean ±
SEM. Three-way, factorial, multivariate analysis of variance
(ANOVA) for repeated measures with the Bonferroni adjust-
ment (SPSS for Windows 7.5, SPSS Inc, Chicago, Ill) was
used for statistical analysis of group and time effects. When
group effects were significant (P < .05), 2-way ANOVAs
between the control group and each experimental group (sep-
arately) were used to establish significant differences. The
unpaired t statistic was used for specific comparisons at spe-
cific time points between groups when the group effect was
significant according to 2-way ANOVA (with Bonferroni
adjustment). The paired Student t test with Bonferroni cor-
rection was used for analysis of differences within groups
when the time effect was significant according to multivari-
ate ANOVA and 1-way ANOVA.
Results
No consistent differences were observed between
groups in cardiac output, heart rate, and arterial, central
venous, or pulmonary arterial pressures. All these val-
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Fig 1. Platelet counts (mean ± SEM) corrected for dilution at
8 sampling points. Open circles represent control group
(group 1); filled triangles represent NO only (group 2); filled
squares represent NO plus eptifibatide (group 3). Base,
Baseline; HEP, after heparin and drugs, before CPB; START,
5 minutes after starting CPB; END, 55 minutes after starting
CPB; PROT, 10 minutes after protamine administration (25
minutes after stopping CPB); 30, 30 minutes after time PROT;
60, 60 minutes after time PROT; 120, 120 minutes after time
PROT. Table I gives statistics.
ues remained within reference ranges at all time points
(data not shown).
Both group and time effects for changes in platelet
count were significant (Table I). In control animals
platelet counts were significantly lower than baseline at
the end of CPB and thereafter and were significantly
lower than platelet counts in each of the other 2 groups
after CPB (Fig 1). NO alone did not significantly inhibit
platelet aggregation during CPB but preserved platelet
function after CPB significantly with respect to that in
control animals. The combination of NO and eptifibatide
completely suppressed platelet function at the beginning
of CPB, but function recovered and was significantly bet-
ter than control values when protamine was given. NO,
alone or in combination with eptifibatide, suppressed
release of b TG during CPB, and plasma b TG concentra-
tions were significantly lower at the end of CPB in
groups 2 and 3 than in the control group (Fig 2, Table I).
In control baboons bleeding times were nearly 4 times
longer than baseline at the time that protamine was given,
and they remained significantly elevated 2 hours later
(Table I, Fig 3). Differences in bleeding times between
control animals and baboons in both experimental groups
were highly significant (P < .002) at all time points after
CPB. The combination of drugs returned bleeding times
to nearly baseline at the time that protamine was given (P
= .032) and returned them completely to baseline 30 min-
utes later (P = 1.000). Although the mean bleeding time
at the time that protamine was given was 3 minutes less
with both drugs than with NO alone, the difference
between groups was not significant (P = .693). There
were no significant differences according to 2-way
ANOVA between NO alone and NO in combination with
eptifibatide for any measurement.
Both markers of thrombin formation (fragment 1.2
and thrombin-antithrombin complex) increased during
CPB, but there were no differences between groups at
any time point. Methemoglobin increased to 1.28% ±
0.2% at the end of CPB in group 2 animals and was
0.6% ± 0.1% at the time that protamine was given.
Discussion
NO stimulates soluble guanylate cyclase to increase
platelet guanosine 3´,5´-monophosphate (cGMP),
which inhibits platelet aggregation and adhesion and
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Fig 2. Plasma b TG concentrations (mean ± SEM). Open cir-
cles represent control group (group 1); filled triangles repre-
sent NO only (group 2); filled squares represent NO plus
eptifibatide (group 3). Base, Baseline; HEP, after heparin and
drugs, before CPB; START, 5 minutes after starting CPB;
END, 55 minutes after starting CPB; PROT, 10 minutes after
protamine administration (25 minutes after stopping CPB);
60, 60 minutes after time PROT.
Fig 3. Bleeding times (mean ± SEM). Open circles represent
control group (group 1); filled triangles represent NO only
(group 2); filled squares represent NO plus eptifibatide
(group 3); filled circles represent high-dose eptifibatide data
from Suzuki and associates.11 Base, Baseline; Prot, 10 min-
utes after protamine administration (25 minutes after stop-
ping CPB); 30, 30 minutes after time Prot; 60, 60 minutes
after time Prot; 120, 120 minutes after time Prot. Bleeding
times were not measured during CPB.
also inhibits cGMP-inhibited cyclic adenosine 3´,5´-
monophosphate) phosphodiesterase activity.18,19 Inhib-
ition of this phosphodiesterase increases platelet cyclic
adenosine monophosphate,20 which decreases cytosolic
calcium ion and inhibits the basic platelet reaction that
includes aggregation, adhesion, secretion of dense and
a -granule contents, and release of acid hydrolases.21
NO is rapidly metabolized by hemoglobin8 and has a
half-life in blood of less than 1 second. None of the
metabolites of NO are known to be vasodilators.8
Eptifibatide reversibly inhibits the platelet GpIIb/IIIa
receptor and inhibits binding to fibrinogen, von
Willebrand factor, and other ligands for this receptor.9
Eptifibatide is partially cleared by the kidney and has a
half-life in plasma of approximately 90 minutes.22
The rationale for using both NO and eptifibatide for
platelet anesthesia during CPB is based on the potential
for synergistic activity12 and the relative short plasma
half-lives of both drugs. In this baboon model no surgi-
cal wound was present; in clinical cardiac surgery with
CPB the wound is a major stimulus for thrombin for-
mation and platelet activation.23 Because NO is metab-
olized so rapidly, its effect may be limited to the oxy-
genator and arterial portion of the CPB circuit.8
Platelets exposed to the wound therefore may not be
inhibited by NO alone. Mellgren and colleagues24
found that 40 ppm NO inhibited expression of the
platelet GpIb receptor during cardiac surgery in
patients but did not inhibit any other marker of platelet
activation. During in vitro perfusion lasting 24 hours
the same investigators found that concentrations of NO
between 15 and 75 ppm protected platelet counts and
reduced b TG release but did not reduce GpIb expres-
sion or serotonin release.25 Mellgren and colleagues’
data24,25 indicate that NO alone is not sufficient to pro-
vide platelet anesthesia during clinical cardiac surgery
with CPB. The current study failed to demonstrate a
synergistic effect between NO and eptifibatide during
CPB, but this result does not negate the rationale for
using this combination clinically because a major
wound was absent.
In a previous study eptifibatide alone significantly
shortened postoperative bleeding times with respect to
control values at the time of protamine administration
but did not restore preoperative bleeding times until 60
minutes after protamine administration (85 minutes
after CPB11; Fig 3). When eptifibatide was combined
with low-dose iloprost (Berlex Laboratories; Cedar
Knolls, NJ), bleeding time was 5.8 ± 0.6 minutes at the
time of protamine administration (versus 5.1 ± 1.2 min-
utes with NO plus eptifibatide in this study) and was not
significantly different from baseline values. High-dose
eptifibatide alone attenuated b TG release, but low-dose
eptifibatide in combination with iloprost did not.11
Together, these 2 studies indicate that in the baboon
model eptifibatide is just as efficacious as NO in inhibit-
ing aggregation and adhesion but is not as effective in
suppressing a -granule release at the doses used.
NO and chemical donors of NO have been used in a
variety of clinical applications, including acute respira-
tory distress syndrome,26 pulmonary hypertension,27
lung transplantation, congenital heart surgery, left ven-
tricular circulatory assistance, and post-CPB cardiac
surgery. Eptifibatide has been used safely and effective-
ly for treatment of acute coronary arterial syndromes.28
In moderate doses (approximately 20 ppm) NO
administered to the natural lung selectively dilates the
pulmonary vasculature, but if given for prolonged peri-
ods NO is toxic because of its oxidant metabolites,
NO2– and NO3–.27 Selective pulmonary vasodilation
with minimal systemic vasodilation is due to rapid
binding to hemoglobin to form S-nitrosyl hemoglobin
and methemoglobin.8 Short-term administration of NO
for clinical cardiac surgery is not likely to seriously
interfere with oxygen delivery; in animals doses
between 500 and 1000 ppm have been used for as long
as 90 minutes.29 Very high doses, however, decrease
rather than increase the platelet inhibitory effect of the
drug. The mechanism may be related to increasing
platelet cGMP above concentrations that inhibit
cGMP-inhibited cyclic adenosine monophosphate
phosphodiesterase.19
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